Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 25 September 2012 | By Louise Zornoza
Australia's Therapeutic Goods Administration (TGA) has announced planned amendments to the regulatory requirements for making minor variations to registered prescription drugs.
Minor variations include any changes not requiring clinical, nonclinical or quality data to be submitted to regulators, and are typically submitted to TGA under what is known as the Streamlined Submission Process.
Under TGA's newly amended regulatory requirements, minor variations will be classified as either Safety-Related Requests (SRRs) or Self-Assessable Requests (SARs) for variations that are not safety related, and both will require prior TGA approval.
There will be a three-month transition period, during which the TGA will:
The TGA will be issuing guidance on the new regulatory process.
Tags: Minor Variations, Amendments, Latest News, australia, regulations